Johnson & Johnson (JNJ) Earnings

Johnson & Johnson

JNJ · NYSE

Sep 2026upcoming

Next quarter

Expected to report Oct 13, 2026 — estimated from last year’s reporting date.

Consensus is $3.04 EPS for Sep 2026 across 6 estimates, ranging $2.94 to $3.14.

JNJ Jun 2026

Reported Jul 15, 2026

: 2.11%
: +1.19%

: $2.84
: $2.90
: —
: $25.31B

Reported results

: $25.31B; from $23.74B
: 68.19%; from 67.87%
: $5.53B; from $5.54B
: $2.27; from $2.29

Our read on this quarter has not been written yet. The filed figures and the source documents are above and below.

Symbol: JNJ
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Key Issues

Bullish view

Strong second-quarter growth from Darzalex, Erleada, and newer cancer drugs supports J&J’s long-term growth ambitions and can strengthen Innovative Medicine.

Bearish view

The evidence does not quantify oncology’s contribution or offsetting pressures from patent expirations, leaving uncertainty over how durable the reported growth will be.

Analyst Consensus

See all

Buy

22 analysts

$258

Current

—

Low

$278

Average

—

High

Average target implies +7.92% versus the current price.

Earnings History

BeatMissNo estimate

Peers

AbbVie Inc.ABBV · NYSE